9UA Stock Chart & Stats
€1.38
-€0.05(-3.50%)
At close: 4:00 PM EDT
€1.38
-€0.05(-3.50%)
Day’s Range― - ―
52-Week Range€1.27 - €5.00
Previous CloseN/A
Volume0.00
Average Volume (3M)821.00
Market Cap
€203.97M
Enterprise Value€129.26
Total Cash (Recent Filing)€86.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding107,522,640
10 Day Avg. Volume1,284
30 Day Avg. Volume821
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)159.85
Price to Sales (P/S)0.00
P/FCF Ratio-28.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.71Price Target Upside676.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces fixed financial obligations and interest pressure, preserving flexibility to direct available capital toward NVG-291 development and limiting balance-sheet risk during clinical execution.
Improved Cash PositionThe substantially larger cash balance provides funding capacity for ongoing trials and operations, potentially reducing near-term financing urgency even though continued development spending remains substantial.
Focused Clinical PipelineConcentrating resources on NVG-291 gives the company a clear development priority and preserves the potential to create future licensing or commercial value if clinical and regulatory milestones are achieved.
Bears Say
Pre-Revenue BusinessWith no recurring product revenue, NervGen lacks internally generated funding and remains dependent on clinical progress, external capital, or future partnerships to support its operations and development pipeline.
Widening Losses And Cash BurnRising losses and negative operating cash flow indicate that spending is increasing faster than any operating inflow, creating sustained funding requirements and reducing financial resilience if capital markets weaken.
Dilution And Financing RiskOngoing reliance on equity issuance can dilute existing holders, while the expanded warrant liability adds financial complexity and volatility as the company funds a capital-intensive clinical program.
NervGen Pharma News
9UA FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was €1.27 and its highest was €5.00 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is €203.97M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Aug 13, 2026. The company reported -€0.227 earnings per share for the quarter, missing the consensus estimate of -€0.052 by -€0.175.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.08.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 107,522,640 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -€0.227 in its last earnings report, missing expectations of -€0.052. Following the earnings report the stock price went up 2.837%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in DE:9UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.71 (676.17% Upside)
€10.71 (676.17% Upside)
Blogger Sentiment
Bullish
DE:9UA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €1.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
412.55%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
9UA Stock 12 Month Forecast
Average Price Target
€10.71
▲(676.17% Upside)
Technical Analysis
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―